Wall Street Underestimates Novo Nordisk's GLP-1 Comeback

Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well as the weak performance of its long-acting insulin franchise. So, sales of Ozempic fell 12.6% quarter-on-quarter and 15% YoY to about DKK 27.83 billion in Q1.